Answers are grounded in this paper and cite their sources.
Supports TAVR feasibility in high-risk patients; leaves open questions on optimal selection and long-term outcomes.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Gilard et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: